Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer

Journal of Clinical Oncology

Volumn 17, Issue 12, 1999, Pages 3822-3827

  Fokkema, E ^a   Groen, H J M ^a   Bauer, J ^a   Uges, D R A ^a   Weil, C ^a   Smith, I E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

SATRAPLATIN;

ADULT; AGED; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; LUNG SMALL CELL CANCER; MALE; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0032791924     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.12.3822     Document Type: Article

References (42)

1. Twentyman PR, Wright KA, Mistry P, et al: Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res 52:5674-5680, 1992
2. Mellish KJ, Kelland LR, Harrap KR: In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer 68:240-250, 1993
3. Raynaud FI, Mistry P, Donaghue A, et al: Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother Pharmacol 38:155-162, 1996
4. Orr RM, O'Neill CF, Nicolson MC, et al: Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin. Br J Cancer 70:415-420, 1994
5. Kelland LR, Abel G, McKeage MJ, et al: Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): An orally active platinum drug. Cancer Res 53:2581-2586, 1993
6. McKeage MJ, Mistry P, Ward J, et al: A phase I and pharmacology study of an oral platinum complex, JM216: Dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 36:451-458, 1995
7. McKeage MJ, Morgan SE, Boxall FE, et al: Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents. Br J Cancer 67:996-1000, 1993
8. McKeage MJ, Boxall FE, Jones M, et al: Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexylamine-platinum(IV) in comparison to cisplatin and tetraplatin in the rat. Cancer Res 54:629-631, 1994
9. McKeage MJ, Raynaud F, Ward J, et al: Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 15:2691-2700, 1997
10. McKeage MJ, Morgan SE, Boxall FE, et al: Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: Ammine/amine platinum(IV) dicarboxylates. Cancer Chemother Pharmacol 33:497-503, 1994
11. Beale P, Raynaud F, Hanwell J, et al: Phase I study of oral JM216 given twice daily. Cancer Chemother Pharmacol 42:142-148, 1998
12. McKeage MJ, Kelland LR, Boxall FE, et al: Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexyl-amine-platinum(IV) (JM216) in vivo. Cancer Res 54:4118-4122, 1994
13. World Health Organization: Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No.48. Den Haag, the Netherlands, Nijhoff, 1979
14. Roberts JJ, Fraval HNA: Repair of cis-platinum (II) diamminedichloride-induced DNA damage and cell sensitivity, in Prestayko AW, Crooke ST, Carter SK (eds): Cisplatin Current Status and New Developments. New York, NY, Academic Press, 1999, pp 57-77
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Sasaki Y, Shinkai T, Eguchi K, et al: Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay. Cancer Chemother Pharmacol 27:263-270, 1991
17. Grant SC, Gralla RJ, Kris MG, et al: Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: The case for studies in previously treated patients. J Clin Oncol 10:484-498, 1992
18. Cavalli F, Goldhirsch A, Siegenthaler P, et al: Phase-II study with cis-dichlorodiammineplatinum (II) in small cell anaplastic bronchogenie carcinoma. Eur J Cancer 16:617-621, 1980
19. Jacobs RH, Bitran JD, Deutsch M, et al: Phase II study of carboplatin in previously untreated patients with metastatic small cell lung carcinoma. Cancer Treat Rep 71:311-312, 1987
20. Tamura T, Saijo N, Shinkai T, et al: Phase II study of carboplatin in small cell lung cancer. Jpn J Clin Oncol 18:27-32, 1988
21. Smith IE, Harland SJ, Robinson BA, et al: Carboplatin: A very active new cisplatin analog in the treatment of small cell lung cancer. Cancer Treat Rep 69:43-46, 1985
22. Smith IE, Evans BD: Carboplatin (JM8) as a single agent and in combination in the treatment of small cell lung cancer. Cancer Treat Rev 12:73-75, 1985
23. Japan Cooperative Oncology Group on Lung Cancer: Phase II study of carboplatin in patients with nonresected lung cancer. Cancer Chemother Pharmacol 26:101-104, 1990
24. Kramer BS, Birch R, Greco A, et al: Randomized phase II evaluation of iproplatin (CHIP) and carboplatin (CBDCA) in lung cancer: A Southeastern Cancer Study Group trial. Am J Clin Oncol 11:643-645, 1988
25. Carney DN, Grogan L, Smit EF, et al: Single-agent oral etoposide for elderly small cell lung cancer patients. Semin Oncol 17:49-53, 1990
26. Smit EF, Carney DN, Harford P, et al: A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax 44:631-633, 1989
27. Souhami RL, Spiro SG, Rudd RM, et al: Five-day oral etoposide treatment for advanced small-cell lung cancer: Randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 89:577-580, 1997
28. Girling DJ: Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomised trial - Medical Research Council Lung Cancer Working Party. Lancet 348:563-566, 1996
29. Rose WC: Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models. Cancer Chemother Pharmacol 40:51-56, 1997
30. Koeller JM, Trump DL, Tutsch KD, et al: Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion. Cancer 57:222-225, 1986
31. Foster BJ, Clagett Carr K, Leyland Jones B, et al: Results of NCI-sponsored phase I trials with carboplatin. Cancer Treat Rev 12:43-49, 1985 (suppl A)
32. Curt GA, Grygiel JJ, Corden BJ, et al: A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240). Cancer Res 43:4470-4473, 1983
33. Gore ME, Calvert AH, Smith LE: High dose carboplatin in the treatment of lung cancer and mesothelioma: A phase I dose escalation study. Eur J Cancer Clin Oncol 23:1391-1397, 1987
34. Calvert AH, Harland SJ, Newell DR, et al: Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev 12:51-57, 1985 (suppl A)
35. Boni C, Cocconi G, Bisagni G, et al: Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer: A phase II trial. Cancer 63:638-642, 1989
36. Ihde DC: Small cell lung cancer: State-of-the-art therapy 1994. Chest 107:2435-2485, 1995
37. Murphy PB, Hainsworth JD, Greco FA, et al: A phase II trial of cisplatin and prolonged administration of oral etoposide in extensive-stage small cell lung cancer. Cancer 69:370-375, 1992
38. Evans WK, Shepherd FA, Feld R, et al: First-line therapy with VP-16 and cisplatin for small-cell lung cancer. Semin Oncol 13:17-23, 1986
39. Evans WK, Radwi A, Tomiak E, et al: Oral etoposide and carboplatin: Effective therapy for elderly patients with small cell lung cancer. Am J Clin Oncol 18:149-155, 1995
40. Evans WK, Eisenhauer E, Hughes P, et al: VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group. Br J Cancer 58:464-468, 1988
41. Bishop JF, Raghavan D, Stuart HR. et al: Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer. J Clin Oncol 5:1574-1578, 1987
42. Smith IE, Evans BD, Gore ME, et al: Carboplatin (Paraplatin: JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol 5:185-189, 1987